ABSTRACT
Among children with multiple congenital melanocytic nevi, 25% have no established genetic cause, of whom many develop a hyperproliferative and severely pruritic phenotype resistant to treatment. Gene fusions have been reported in individual cases of congenital melanocytic nevi. We studied 169 patients with congenital melanocytic nevi in this study, 38 of whom were double wild type for pathogenic NRAS/BRAF variants. Nineteen of these 38 patients had sufficient tissue to undergo RNA sequencing, which revealed mosaic BRAF fusions in 11 of 19 patients and mosaic RAF1 fusions in 1 of 19. Recurrently, fusions involved the loss of the 5´ regulatory domain of BRAF or RAF1 but preserved the kinase domain. We validated all cases and detected the fusions in two separate nevi in 5 of 12 patients, confirming clonality. The absence of the fusion in blood in 8 of 12 patients indicated mosaicism. Primary culture of BRAF-fusion nevus cells from 3 of 12 patients demonstrated highly increased MAPK activation, despite only mildly increased BRAF expression, suggesting additional mechanisms of kinase activation. Trametinib quenched MAPK hyperactivation in vitro, and treatment of two patients caused rapid improvement in bulk tissue, improving bodily movement and reducing inflammation and severe pruritus. These findings offer a genetic diagnosis to an additional group of patients and trametinib as a treatment option for the severe associated phenotypes.
Subject(s)
Nevus, Epithelioid and Spindle Cell , Nevus, Pigmented , Skin Neoplasms , Child , Humans , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , Proto-Oncogene Proteins B-raf/genetics , Mutation , Nevus, Pigmented/drug therapy , Nevus, Pigmented/genetics , Nevus, Pigmented/congenitalSubject(s)
Nevus, Pigmented , Skin Neoplasms , Humans , Proto-Oncogene Proteins B-raf/genetics , Nevus, Pigmented/drug therapy , Nevus, Pigmented/genetics , Nevus, Pigmented/congenital , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , Skin Neoplasms/congenital , Mutation/genetics , Repressor Proteins/genetics , Transcription Factors/genetics , Homeodomain Proteins/geneticsABSTRACT
A 29 year old woman with cystic fibrosis (CF) presented to CF clinic following the sudden development of over 200 pigmented naevi located predominately on the trunk and limbs 3 months after commencing elexacaftor/tezacaftor/ivacaftor, a novel triple-therapy CFTR modulator therapy for CF. Skin biopsy confirmed benign naevi and the clinical presentation was consistent with eruptive melanocytic naevi. Elexacaftor/tezacaftor/ivacaftor received marketing authorisation in August 2020 and this is the first report of associated naevi. The individual described here remains clinically well, and continues on elexacaftor/tezacaftor/ivacaftor with dermatology follow-up.
Subject(s)
Cystic Fibrosis , Nevus, Pigmented , Skin Neoplasms , Female , Humans , Adult , Cystic Fibrosis/drug therapy , Chloride Channel Agonists/adverse effects , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Mutation , Nevus, Pigmented/drug therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/drug therapyABSTRACT
Giant congenital melanocytic nevi are NRAS-driven proliferations that may cover up to 80% of the body surface. Their most dangerous consequence is progression to melanoma. This risk often triggers preemptive extensive surgical excisions in childhood, producing severe lifelong challenges. We have presented preclinical models, including multiple genetically engineered mice and xenografted human lesions, which enabled testing locally applied pharmacologic agents to avoid surgery. The murine models permitted the identification of proliferative versus senescent nevus phases and treatments targeting both. These nevi recapitulated the histologic and molecular features of human giant congenital nevi, including the risk of melanoma transformation. Cutaneously delivered MEK, PI3K, and c-KIT inhibitors or proinflammatory squaric acid dibutylester (SADBE) achieved major regressions. SADBE triggered innate immunity that ablated detectable nevocytes, fully prevented melanoma, and regressed human giant nevus xenografts. These findings reveal nevus mechanistic vulnerabilities and suggest opportunities for topical interventions that may alter the therapeutic options for children with congenital giant nevi.
Subject(s)
Melanoma , Nevus, Pigmented , Skin Neoplasms , Animals , Heterografts , Humans , Melanoma/drug therapy , Melanoma/pathology , Mice , Neoplasm Transplantation , Nevus, Pigmented/congenital , Nevus, Pigmented/drug therapy , Nevus, Pigmented/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Skin Neoplasms/prevention & controlABSTRACT
DNA damage plays a role in ultraviolet (UV)-induced melanoma. We previously showed that aspirin (ASA) can suppress prostaglandin-E2 (PGE2) and protect melanocytes from UV-induced DNA damage in mice, and suggested that taking ASA before acute sun exposure may reduce melanoma risk. We conducted a prospective randomized placebo-controlled trial to determine if orally administered ASA could suppress PGE2 in plasma and nevi and protect nevi from UV-induced DNA damage. After obtaining plasma and determining the minimal erythemal dose (MED) in 95 subjects at increased risk for melanoma, they were randomized to receive a daily dose of placebo, 81 mg ASA, or 325 mg ASA, in double-blind fashion for one month. After this intervention, one nevus was irradiated (dose = 1 or 2 MED) using a solar simulator. One day later, MED was re-determined, a second plasma sample was obtained, and the UV-irradiated nevus and an unirradiated nevus were removed. ASA metabolites were detected in the second plasma sample in subjects in the ASA arms. There were no significant differences in the pre- and post-intervention MED between those patients receiving ASA and placebo. Significantly reduced PGE2 levels were detected in plasma (second vs. first samples) and in nevi (both unirradiated and UV-treated) in subjects receiving ASA compared to placebo. Comparing UV-treated nevi from the ASA and placebo cohorts, however, did not reveal significant reductions in CD3-cell infiltration or 8-oxoguanine and cyclobutane pyrimidine dimers. Thus ASA did not effectively protect nevi from solar-simulated UV-induced inflammation and DNA damage under the conditions examined. PREVENTION RELEVANCE: Despite promising rationale, ASA at conventional dosing was not able to protect nevi against UV-induced DNA damage under the conditions examined.See related Spotlight, p. 71.
Subject(s)
Nevus, Pigmented , Skin Neoplasms , Humans , Aspirin/therapeutic use , DNA Damage , Nevus, Pigmented/drug therapy , Nevus, Pigmented/prevention & control , Prospective Studies , Skin Neoplasms/genetics , Ultraviolet Rays/adverse effectsABSTRACT
Large/giant congenital nevi (L/GCMN) are benign neoplasms of the melanocytic neural crest lineage covering extensive areas of skin presenting risk for melanoma. Surgical resection often leads to scarring and trauma. Histone deacetylase inhibitors (iHDACs) as topical therapeutic agents may prove beneficial as an alternative/adjunct to surgery in this disease. Here we describe the effect of in vitro treatment of iHDACs drugs on primary nevocytes isolated from L/GCMN patients. Micropthalmia transcription factor (MITF) expression in L/GCMN patients' lesions was detected by immunohistochemistry, in cultured nevocytes by immunofluorescence, immunoblot and quantitative polymerase chain reaction. Cellular senescence was detected by SA-ß galactosidase activity. Markers for melanocytic differentiation were evaluated by immunoblot analysis and extracted melanin content was estimated spectrophotometrically. Cell death was measured by lactate dehydrogenase (LDH) assay and necrosis confirmed by polymerase (PARP) cleavage and acridine orange staining of the nuclei. MITF was expressed ubiquitously in nevocytes and melanocytes in patients' lesions. In culture, iHDAC treatment suppressed MITF protein and mRNA expression resulting in a senescent-like phenotype with positive ß-galactosidase staining, progressing to necrotic cell death as evidenced by increased LDH activity, appearance of cleaved PARP and necrotic nuclei. This is the first report showing evidence of iHDACs-induced MITF suppression in congenital nevocytes in vitro leading to a morphologic change with positive ß-galactosidase staining, followed by necrotic cell death in nevocytes, indicating that iHDAC drugs could be valuable therapeutic agents for treatment of L/GCMN lesions.
Subject(s)
Histone Deacetylase Inhibitors/therapeutic use , Nevus, Pigmented/drug therapy , Skin Neoplasms/drug therapy , Transcription Factors/drug effects , Vorinostat/therapeutic use , Cell Death , Cell Differentiation , Child, Preschool , Histone Deacetylase Inhibitors/pharmacology , Humans , Infant , Vorinostat/pharmacologyABSTRACT
PURPOSE: To describe the occurrence of an acquired choroidal nevus in a 73-year-old white man. METHODS: Case report. RESULTS: A 73-year-old white man was referred for an evaluation and treatment of macular changes in his left eye consistent with pachychoroid neovasculopathy. Baseline funduscopic examination and color fundus photographs showed two small peripheral choroidal nevi in the right eye and a single small choroidal nevus in the far temporal macula of the left eye. Treatment with intravitreal aflibercept was initiated in the left eye on a treat-and-extend dosing regimen. Approximately 1 year later, a new pigmented choroidal lesion was detected in the left macula in an area where previous high-resolution color fundus photographs had shown no abnormal pigmentation. Swept-source optical coherence tomography of the new pigmented lesion showed flat hyperreflectivity within the inner choroid consistent with a small choroidal nevus. The patient was referred to his internist who found no evidence of an occult malignancy. Over the course of more than 4 additional years of continuous follow-up, the new choroidal nevus remained stable, no new fundus abnormalities were detected in either eye, and the patient remained medically stable. CONCLUSION: To the best of our knowledge, this is the first documented case of a new choroidal nevus. Multimodal imaging performed before lesion detection and over the ensuing 4 years showed its stability, thus allowing for the conclusion that it was a benign choroidal nevus rather than a neoplastic or paraneoplastic process.
Subject(s)
Choroid Neoplasms/diagnosis , Nevus, Pigmented/diagnosis , Aged , Angiogenesis Inhibitors/therapeutic use , Choroid Neoplasms/drug therapy , Documentation , Fluorescein Angiography , Follow-Up Studies , Humans , Male , Multimodal Imaging , Nevus, Pigmented/drug therapy , Ophthalmoscopy , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Tomography, Optical Coherence , Visual AcuitySubject(s)
Melanoma , Nevus, Pigmented , Skin Neoplasms , Adult , Humans , Ipilimumab , Melanoma/drug therapy , Nevus, Pigmented/drug therapy , Skin Neoplasms/drug therapyABSTRACT
Methyl-CpG binding domain protein 3 (MBD3) belongs to the methyl-CpG binding protein family. MBD3 facilitates the initiation of neural stem cell reprogramming. Melanoma originates in melanocytes derived from neural crest stem cells; therefore, we investigated the role of MBD3 in melanoma. MBD3 was overexpressed in melanoma compared with pigmented nevi. MBD3 knockdown had no effect on the proliferation of melanoma cells (A375 and A2058 cells). Contrarily, it significantly reduced the migration and invasion of A375 cells, but had no significant effect on A2058 cells. Furthermore, MBD3 knockdown reduced N-cadherin protein levels and matrix metalloproteinase-2 (MMP-2) activity in A375 cells, but had no significant effect on A2058 cells. Based on these results, the MBD3 expression level may be a useful biomarker for the diagnosis of melanoma. Thus, MBD3 has potential as a novel therapeutic target for some melanoma patients.
Subject(s)
Biomarkers, Tumor/metabolism , DNA-Binding Proteins/metabolism , Melanoma/diagnosis , Nevus, Pigmented/diagnosis , Skin Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/analysis , Biomarkers, Tumor/antagonists & inhibitors , Biomarkers, Tumor/genetics , Cell Line, Tumor , Cell Movement/genetics , DNA-Binding Proteins/analysis , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/genetics , Diagnosis, Differential , Epigenesis, Genetic/drug effects , Female , Gene Knockdown Techniques , Humans , Male , Melanoma/drug therapy , Melanoma/pathology , Middle Aged , Neoplasm Invasiveness/genetics , Neoplasm Invasiveness/pathology , Nevus, Pigmented/drug therapy , Nevus, Pigmented/pathology , Skin/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathologyABSTRACT
Antineoplastic agents that use the immune system have revolutionized cancer treatment. Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T-lymphocyte-associated antigen-4, programmed cell death protein 1, or programmed cell death ligand 1 show improved and sustained responses in patients with cancer. However, these agents are associated with a plethora of adverse events, many manifesting in the skin. As the clinical application of cancer immunotherapies expands, understanding the clinical and histopathologic features of associated cutaneous toxicities becomes increasingly important to dermatologists, oncologists, and pathologists to ensure timely diagnosis and appropriate care. This review discusses cutaneous reactions to immune checkpoint inhibitors, focusing on histopathologic features.
Subject(s)
Drug Eruptions/etiology , Immune Checkpoint Inhibitors/adverse effects , Acantholysis/chemically induced , Acantholysis/pathology , Alopecia/chemically induced , Alopecia/pathology , Drug Eruptions/pathology , Humans , Keratinocytes/drug effects , Lichenoid Eruptions/chemically induced , Lichenoid Eruptions/pathology , Nevus, Pigmented/drug therapy , Panniculitis/chemically induced , Panniculitis/pathology , Pemphigoid, Bullous/chemically induced , Pemphigoid, Bullous/pathology , Pruritus/chemically induced , Pruritus/pathology , Psoriasis/chemically induced , Psoriasis/pathology , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/pathology , Vitiligo/chemically induced , Vitiligo/pathologyABSTRACT
Melanin-related compounds in paraffin-embedded tissue specimens of basal cell carcinoma (BCC), seborrheic keratosis (SK), malignant melanoma (MM), and nevus pigmentosus (NP) were nondestructively investigated using permeability measurements (light penetration into pigmented lesion), X-band (9.4 GHz) electron paramagnetic resonance (EPR), and EPR imaging (EPRI). The paramagnetic species in BCC, SK, MM, and NP specimens were analyzed using intensity, linewidth, spectral pattern, and X-band EPRI. The EPR spectra of BCC, SK, and NP showed a single line pattern. The EPR signal intensities of the BCC, SK, and NP samples corresponded to the permeability values that are directly related to pigment color tone, except for MM. The correlation coefficient between EPR and permeability was supported by the high degree of linear relation in the range. We further analyzed MM and speculated that MM contains an additional signal of the pheomelanin radical. In MM and NP samples, two-dimensional (2D) EPRI revealed paramagnetic species distribution and different magnitudes. The paramagnetic (radical) species are directly related to the pigmented lesion site. To conclude, spectroscopic analyses suggest that pheomelanin-related compounds may exist in malignant melanoma.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Keratosis, Seborrheic/drug therapy , Melanins/therapeutic use , Nevus, Pigmented/drug therapy , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/chemistry , Carcinoma, Basal Cell/diagnosis , Electron Spin Resonance Spectroscopy , Female , Humans , Keratosis, Seborrheic/diagnosis , Male , Melanins/chemistry , Middle Aged , Molecular Structure , Nevus, Pigmented/diagnosis , Permeability/drug effects , Skin Neoplasms/diagnosis , Young AdultSubject(s)
Choroid Neoplasms/drug therapy , Melanoma/drug therapy , Nevus, Pigmented/drug therapy , Nivolumab/therapeutic use , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Skin Neoplasms/drug therapy , Choroid Neoplasms/diagnostic imaging , Choroid Neoplasms/pathology , Humans , Male , Middle Aged , Nevus, Pigmented/diagnostic imaging , Nevus, Pigmented/pathology , Tomography, Optical Coherence , Melanoma, Cutaneous MalignantABSTRACT
The management of large congenital melanocytic nevi (lCMN) is based exclusively on iterative surgical procedures in the absence of validated medical therapy. The aim of our study was to develop an intra-lesional medical treatment for lCMN. Seventeen patients harboring NRAS-mutated lCMN were included. Nevocytes obtained from lCMN displayed an overactivation of mitogen-activated protein kinase and phosphoinositide 3-kinase (Akt) pathways. Mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) and Akt inhibitors reduced the nevosphere diameter in sphere-forming assays, as well as cell viability and proliferation in in vitro assays. Standardized lCMN explants were then cultured ex vivo with the same inhibitors, which induced a decrease in MelanA+ and Sox10+ cells in both epidermis and dermis. Finally, intradermal injections of these inhibitors were administered within standardized lCMN xenografts in Rag2-/- mice. They induced a dramatic decrease in nevocytes in treated xenografts, which persisted 30 days after the end of treatment. Using original nevus explant and xenograft preclinical models, we demonstrated that intradermal MEK/Akt inhibition might serve as neoadjuvant therapy for the treatment of NRAS-mutated congenital melanocytic nevi to avoid iterative surgeries.
Subject(s)
Antineoplastic Agents/administration & dosage , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Nevus, Pigmented/drug therapy , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Skin Neoplasms/drug therapy , Animals , Cell Proliferation/drug effects , Child , Child, Preschool , Female , GTP Phosphohydrolases/genetics , Humans , Infant , Injections, Intradermal , Injections, Intralesional , MART-1 Antigen/metabolism , Male , Melanocytes/drug effects , Melanocytes/pathology , Membrane Proteins/genetics , Mice , Mitogen-Activated Protein Kinase Kinases/metabolism , Nevus, Pigmented/congenital , Nevus, Pigmented/genetics , Nevus, Pigmented/pathology , Proto-Oncogene Proteins c-akt/metabolism , SOXE Transcription Factors/metabolism , Signal Transduction/drug effects , Signal Transduction/genetics , Skin/cytology , Skin/pathology , Skin Neoplasms/congenital , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Tumor Cells, Cultured , Xenograft Model Antitumor AssaysABSTRACT
Giant congenital nevi are melanocytic proliferations of the skin that may be complicated by melanoma, neurocutaneous melanocytosis, pain, pruritus, and disfigurement. Current treatment options include surgical resection and medical management of associated symptoms. There is limited efficacy in these modalities. No effective pharmacologic treatments are available for the treatment of these lesions. We present the case of a 7-year-old girl with a giant congenital melanocytic nevus that had an AKAP9-BRAF fusion and was treated with trametinib, which resulted in rapid resolution of the patient's lifelong, intractable pain and pruritus as well as dramatic improvement in the extent of her nevus.
Subject(s)
Antineoplastic Agents/therapeutic use , Nevus, Pigmented/diagnostic imaging , Nevus, Pigmented/drug therapy , Pyridones/therapeutic use , Pyrimidinones/therapeutic use , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/drug therapy , Child , Female , Humans , Nevus, Pigmented/surgery , Skin Neoplasms/surgery , Treatment OutcomeSubject(s)
Liver Neoplasms/drug therapy , Melanoma/drug therapy , Nevus, Pigmented/drug therapy , Nivolumab/therapeutic use , Skin Neoplasms/drug therapy , Biopsy , Female , Humans , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/secondary , Melanoma/diagnostic imaging , Melanoma/secondary , Middle Aged , Skin/pathology , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Mupirocin/therapeutic use , Nevus, Pigmented/drug therapy , Skin Neoplasms/pathology , Treatment OutcomeSubject(s)
Choroid Neoplasms/diagnosis , Choroidal Neovascularization/diagnosis , Melanoma/diagnosis , Nevus, Pigmented/diagnosis , Aged , Choroid Neoplasms/complications , Choroid Neoplasms/drug therapy , Choroid Neoplasms/pathology , Choroidal Neovascularization/complications , Choroidal Neovascularization/drug therapy , Choroidal Neovascularization/pathology , Diagnosis, Differential , Female , Humans , Intravitreal Injections , Melanoma/complications , Melanoma/drug therapy , Melanoma/pathology , Nevus, Pigmented/complications , Nevus, Pigmented/drug therapy , Nevus, Pigmented/pathology , Ranibizumab/administration & dosage , Retinal Detachment/complications , Retinal Detachment/diagnosis , Retinal Detachment/drug therapy , UltrasonographyABSTRACT
Basal cell carcinoma is the most common non-melanoma skin cancer, and its incidence continues to raise. Although surgery can be considered the mainstay of therapy, new current pharmacological options are available and focus on tumor eradication, maximizing cosmetic results, and functional capacity. Several studies have recently reported on safety and efficacy of topical ingenol mebutate gel, a derivative of the plant Euphorbia Peplus, used to treat actinic keratosis and superficial basal cell carcinoma. In our knowledge, we report for the first time the dermoscopic evaluation of outcome and monitoring of superficial pigmented and non-pigmented basal cell carcinomas in four patients treated by this novel non-ablative agent. Ingenol mebutate gel therapy has showed to be effective and without important side-effects for pigmented and non-pigmented superficial basal cell carcinomas. We emphasize the usefulness of dermoscopy in supporting the clinical diagnosis and excluding the presence of tumor residue or recurrence. In a future scenario, we hope it will be soon possible to follow-up the lesions, after treatment, avoiding post-control biopsy punch.